Randox RX series gains NGSP certification for direct HbA1c testing

July 15, 2019

In a release, Randox Laboratories announced its achievement in being awarded the Manufacturer Certification by the National Glycohemoglobin Standardization Program (NGSP); for direct HbA1c testing on three of its clinical chemistry analyzers: The RX modena, RX imola, and RX daytona+.

NGSP is recommended for laboratories conducting diabetes-related clinical trials and is only granted on the basis of 98 percent accuracy. With the global prevalence of diabetes mellitus increasing rapidly, affecting roughly eight percent of the total population, the achievement of this certification emphasizes that Randox RX series clinical chemistry analyzers correlate with global standards and deliver accurate, reliable, and precise results for direct HbA1c testing; helping clinicians make informed decisions for patients with diabetes.

The Randox automated immunoturbidmetric HbA1c test exhibits accuracy and reproducibility with the added advantages of using liquid reagents with good stability, and on-board pre-treatment of samples. Therefore, enabling an improved method for the rapid direct measurement of HbA1c in human blood.

Randox Direct HbA1c Assay Features: Sample type, latex enhanced immunoassay method, liquid ready to use reagents, and stability. Advantages of the RX series Direct HbA1c Testing includes: Fully automated on-board haemolysis function for HbA1c testing; continuous loading and STAT sample functionality to enhance productivity in the laboratory; low sample volumes requirements; and 1200 tests per hour including ISE.

Visit Randox for more information